Abstract 2537: Application of the proteograph to the identification of differential protein isoform plasma abundance in early lung cancer vs. healthy controls

Lung cancer is the foremost cause of cancer-related deaths world-wide [1]. It affects 100,000 Americans of the smoking population every year of all age groups, particularly those above 50 years of the smoking population [2]. In India, 51,000 lung cancer deaths were reported in 2012, which include 41,000 men and 10,000 women [3]. It is the leading cause of cancer deaths in men; however, in women, it ranked ninth among all cancerous deaths [4]. It is possible to detect the lung cancer at a very early stage, providing a much higher chance of survival for the patients.

Download Full-text

Integration of Anatomic and Pathogenetic Bases for Early Lung Cancer Diagnosis

10.21236/ada468685 ◽

2007 ◽

Author(s):

Wei Qian

Keyword(s):

Lung Cancer ◽

Cancer Diagnosis ◽

Lung Cancer Diagnosis ◽

Early Lung Cancer

Download Full-text

Enhancing the Sensitivity of Fluorescence Bronchoscopy for Early Lung Cancer Detection Using a Fluorescent Deoxyglucose Analog

10.21236/ada594312 ◽

2013 ◽

Author(s):

Rebekah Drezek

Keyword(s):

Lung Cancer ◽

Cancer Detection ◽

Early Lung Cancer ◽

Lung Cancer Detection

Download Full-text

EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer

10.21236/ada594308 ◽

2013 ◽

Author(s):

Jr Loo ◽

Billy W.

Keyword(s):

Lung Cancer ◽

Tumor Hypoxia ◽

Imaging Biomarker ◽

Stereotactic Ablative Radiotherapy ◽

Early Lung Cancer

Download Full-text

Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer

Cancer Biomarkers ◽

10.3233/cbm-210099 ◽

2021 ◽

pp. 1-9

Author(s):

Renren Ouyang ◽

Shiji Wu ◽

Bo Zhang ◽

Ting Wang ◽

Botao Yin ◽

...

Keyword(s):

Lung Cancer ◽

Lung Disease ◽

Cytokeratin 19 ◽

Healthy Controls ◽

Control Groups ◽

Clinical Value ◽

Tumor Associated Antigens ◽

Pathological Subtype ◽

Positive Rate ◽

Diagnosis Of Lung Cancer

BACKGROUND: This study aimed to investigate the efficiency of combining tumor-associated antigens (TAAs) and autoantibodies in the diagnosis of lung cancer. METHODS: The serum levels of TAAs and seven autoantibodies (7-AABs) were detected from patients with lung cancer, benign lung disease and healthy controls. The performance of a new panel by combing TAAs and 7-AABs was evaluated for the early diagnosis of lung cancer. RESULTS: The positive rate of 7-AABs was higher than the single detection of antibody. The positive rate of the combined detection of 7-AABs in lung cancer group (30.2%) was significantly higher than that of healthy controls (16.8%), but had no statistical difference compared with that of benign lung disease group (20.8%). The positive rate of 7-AABs showed a tendency to increase in lung cancer patients with higher tumor-node-metastasis (TNM) stages. For the pathological subtype analysis, the positive rate of 7-AABs was higher in patients with squamous cell carcinoma and small cell lung cancer than that of adenocarcinoma. The levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 211 (CYFRA 211) were significantly higher than that of benign lung disease and healthy control groups. An optimal model was established (including 7-AABs, CEA and CYFRA21-1) to distinguish lung cancer from control groups. The performance of this model was superior than that of single markers, with a sensitivity of 52.26% and specificity of 77.46% in the training group. Further assessment was studied in another validation group, with a sensitivity of 44.02% and specificity of 83%. CONCLUSIONS: The diagnostic performance was enhanced by combining 7-AABs, CEA and CYFRA21-1, which has critical value for the screening and early detection of lung cancer.

Download Full-text